Key result
Chronic aliskiren use reduced systemic arterial pressure and portal pressure in portal hypertensive rats, partly by modulating splanchnic and collateral NO synthase.
Why the study?
Does aliskiren reduce portal pressure in portal hypertensive rats?
Does aliskiren reduce portal pressure in portal hypertensive rats?
Chronic aliskiren use reduces portal pressure in portal hypertensive rats, partly due to the modulation of splanchnic and collateral NO synthase.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for renin inhibition in portal hypertension; human trials required before any clinical consideration.
BACKGROUND: Aliskiren is a direct renin inhibitor used in the treatment for arterial hypertension. It can also augment nitric oxide (NO) production, which plays a crucial role in the pathogenesis of portal hypertension and modulation of porto-systemic collaterals. This study investigated the effects of aliskiren on portal pressure and porto-systemic collaterals of portal vein-ligated (PVL) rats. MATERIALS AND METHODS: Sham-operated and PVL rats received aliskiren (50 mg/kg per day) or distilled water (control) treatment for 10 days. The mean arterial pressure and portal pressure were measured by catheterization of the right femoral artery and mesenteric vein, while the superior mesenteric arterial blood flow was measured by Doppler technique. The left adrenal vein and superior mesentery artery were dissected for mRNA study. The PVL rats also underwent preincubation with (i) Krebs solution (control); (ii) 10(-4) M aliskiren; or (iii) 10(-4) M aliskiren plus nonselective NO inhibitor N(ω)-nitro-L-arginine (10(-4) M), followed by the addition of arginine vasopressin (AVP) to evaluate the collateral vascular responsiveness. RESULTS: Aliskiren had systemic arterial pressure- and portal pressure-lowering effects in PVL rats. Superior mesentery arterial resistance also decreased. The constitutive NO synthase was enhanced in the left adrenal vein and superior mesentery artery after aliskiren treatment. Aliskiren attenuated the collateral vasoconstrictive effects of AVP, but the vasodilatory effects were abolished after nonselective NO synthase inhibition. CONCLUSIONS: Chronic aliskiren use reduces portal pressure in portal hypertensive rats partly due to the modulation of splanchnic and collateral NO synthase.
No takes yet. Share an insight, caveat, or question.
Chang et al. (2011) studied Portal hypertension. Aliskiren vs. Distilled water (control) was evaluated on Portal pressure and porto-systemic collaterals. Chronic aliskiren use reduced systemic arterial pressure and portal pressure in portal hypertensive rats, partly by modulating splanchnic and collateral NO synthase.
Synapse has enriched 10 related papers. Consider them for comparative context: